“Expected Spesolimab Plasma Exposure following Intravenous and Subcutaneous Dosing in Patients with Generalized Pustular Psoriasis” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s359. doi:10.25251/skin.8.supp.359.